{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,11]],"date-time":"2026-11-11T22:04:13Z","timestamp":1794434653396,"version":"4.9.1"},"reference-count":41,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,5,3]],"date-time":"2022-05-03T00:00:00Z","timestamp":1651536000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,5,3]],"date-time":"2022-05-03T00:00:00Z","timestamp":1651536000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100000274","name":"British Heart Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000274","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005617","name":"BHF Centre of Research Excellence, Oxford","doi-asserted-by":"publisher","award":["RE\/13\/1\/30181"],"award-info":[{"award-number":["RE\/13\/1\/30181"]}],"id":[{"id":"10.13039\/501100005617","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000265","name":"Medical Research Council","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000265","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000289","name":"Cancer Research UK","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000289","id-type":"DOI","asserted-by":"publisher"}]},{"name":"US Centers for Disease Control and Prevention Foundation"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Med"],"published-print":{"date-parts":[[2022,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Effective targeted prevention of type 2 diabetes (T2D) depends on accurate prediction of disease risk. We assessed the role of metabolomic profiling in improving T2D risk prediction beyond conventional risk factors.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Nuclear magnetic resonance (NMR) metabolomic profiling was undertaken on baseline plasma samples in 65,684 UK Biobank participants without diabetes and not taking lipid-lowering medication. Among a subset of 50,519 participants with data available on all relevant co-variates (sociodemographic characteristics, parental history of diabetes, lifestyle\u2014including dietary\u2014factors, anthropometric measures and fasting time), Cox regression yielded adjusted hazard ratios for the associations of 143 individual metabolic biomarkers (including lipids, lipoproteins, fatty acids, amino acids, ketone bodies and other low molecular weight metabolic biomarkers) and 11 metabolic biomarker principal components (PCs) (accounting for 90% of the total variance in individual biomarkers) with incident T2D. These 11 PCs were added to established models for T2D risk prediction among the full study population, and measures of risk discrimination (c-statistic) and reclassification (continuous net reclassification improvement [NRI], integrated discrimination index [IDI]) were assessed.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      During median 11.9 (IQR 11.1\u201312.6) years\u2019 follow-up, after accounting for multiple testing, 90 metabolic biomarkers showed independent associations with T2D risk among 50,519 participants (1211 incident T2D cases) and 76 showed associations after additional adjustment for HbA1c (false discovery rate controlled\n                      <jats:italic>p<\/jats:italic>\n                      &lt; 0.01). Overall, 8 metabolic biomarker PCs were independently associated with T2D. Among the full study population of 65,684 participants, of whom 1719 developed T2D, addition of PCs to an established risk prediction model, including age, sex, parental history of diabetes, body mass index and HbA1c, improved T2D risk prediction as assessed by the c-statistic (increased from 0.802 [95% CI 0.791\u20130.812] to 0.830 [0.822\u20130.841]), continuous NRI (0.44 [0.38\u20130.49]) and relative (15.0% [10.5\u201320.4%]) and absolute (1.5 [1.0\u20131.9]) IDI. More modest improvements were observed when metabolic biomarker PCs were added to a more comprehensive established T2D risk prediction model additionally including waist circumference, blood pressure and plasma lipid concentrations (c-statistic, 0.829 [0.819\u20130.838] to 0.837 [0.831\u20130.848]; continuous NRI, 0.22 [0.17\u20130.28]; relative IDI, 6.3% [4.1\u20139.8%]; absolute IDI, 0.7 [0.4\u20131.1]).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>When added to conventional risk factors, circulating NMR-based metabolic biomarkers modestly enhanced T2D risk prediction.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12916-022-02354-9","type":"journal-article","created":{"date-parts":[[2022,5,2]],"date-time":"2022-05-02T21:02:29Z","timestamp":1651525349000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":116,"title":["Predictive value of circulating NMR metabolic biomarkers for type 2 diabetes risk in the UK Biobank study"],"prefix":"10.1186","volume":"20","author":[{"given":"Fiona","family":"Bragg","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eirini","family":"Trichia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diego","family":"Aguilar-Ramirez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jelena","family":"Be\u0161evi\u0107","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah","family":"Lewington","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan","family":"Emberson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,5,3]]},"reference":[{"issue":"7588","key":"2354_CR1","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1136\/bmj.39063.689375.55","volume":"334","author":"CL Gillies","year":"2007","unstructured":"Gillies CL, Abrams KR, Lambert PC, Cooper NJ, Sutton AJ, Hsu RT, et al. Pharmacological and lifestyle interventions to prevent or delay type 2 diabetes in people with impaired glucose tolerance: systematic review and meta-analysis. BMJ. 2007;334(7588):299.","journal-title":"BMJ"},{"issue":"6","key":"2354_CR2","doi-asserted-by":"publisher","first-page":"452","DOI":"10.1016\/S2213-8587(19)30093-2","volume":"7","author":"Q Gong","year":"2019","unstructured":"Gong Q, Zhang P, Wang J, Ma J, An Y, Chen Y, et al. Morbidity and mortality after lifestyle intervention for people with impaired glucose tolerance: 30-year results of the Da Qing diabetes prevention outcome study. Lancet Diabetes Endocrinol. 2019;7(6):452\u201361.","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"10","key":"2354_CR3","doi-asserted-by":"publisher","first-page":"1068","DOI":"10.1001\/archinte.167.10.1068","volume":"167","author":"PW Wilson","year":"2007","unstructured":"Wilson PW, Meigs JB, Sullivan L, Fox CS, Nathan DM, D\u2019Agostino RB Sr. Prediction of incident diabetes mellitus in middle-aged adults: the Framingham offspring study. Arch Intern Med. 2007;167(10):1068\u201374.","journal-title":"Arch Intern Med"},{"issue":"3","key":"2354_CR4","doi-asserted-by":"publisher","first-page":"725","DOI":"10.2337\/diacare.26.3.725","volume":"26","author":"J Lindstr\u00f6m","year":"2003","unstructured":"Lindstr\u00f6m J, Tuomilehto J. The diabetes risk score: a practical tool to predict type 2 diabetes risk. Diabetes Care. 2003;26(3):725\u201331.","journal-title":"Diabetes Care"},{"key":"2354_CR5","doi-asserted-by":"publisher","first-page":"b880","DOI":"10.1136\/bmj.b880","volume":"338","author":"J Hippisley-Cox","year":"2009","unstructured":"Hippisley-Cox J, Coupland C, Robson J, Sheikh A, Brindle P. Predicting risk of type 2 diabetes in England and Wales: prospective derivation and validation of QDScore. BMJ. 2009;338:b880.","journal-title":"BMJ"},{"key":"2354_CR6","doi-asserted-by":"publisher","first-page":"e5900","DOI":"10.1136\/bmj.e5900","volume":"345","author":"A Abbasi","year":"2012","unstructured":"Abbasi A, Peelen LM, Corpeleijn E, van der Schouw YT, Stolk RP, Spijkerman AMW, et al. Prediction models for risk of developing type 2 diabetes: systematic literature search and independent external validation study. BMJ. 2012;345:e5900.","journal-title":"BMJ"},{"key":"2354_CR7","doi-asserted-by":"publisher","first-page":"d7163","DOI":"10.1136\/bmj.d7163","volume":"343","author":"D Noble","year":"2011","unstructured":"Noble D, Mathur R, Dent T, Meads C, Greenhalgh T. Risk models and scores for type 2 diabetes: systematic review. BMJ. 2011;343:d7163.","journal-title":"BMJ"},{"issue":"1","key":"2354_CR8","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1016\/S2213-8587(13)70008-1","volume":"1","author":"K F\u00e6rch","year":"2013","unstructured":"F\u00e6rch K, Witte DR, Tab\u00e1k AG, Perreault L, Herder C, Brunner EJ, et al. Trajectories of cardiometabolic risk factors before diagnosis of three subtypes of type 2 diabetes: a post-hoc analysis of the longitudinal Whitehall II cohort study. Lancet Diabetes Endocrinol. 2013;1(1):43\u201351.","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"5","key":"2354_CR9","doi-asserted-by":"publisher","first-page":"833","DOI":"10.2337\/dc15-2251","volume":"39","author":"M Guasch-Ferr\u00e9","year":"2016","unstructured":"Guasch-Ferr\u00e9 M, Hruby A, Toledo E, Clish CB, Mart\u00ednez-Gonz\u00e1lez MA, Salas-Salvad\u00f3 J, et al. Metabolomics in prediabetes and diabetes: a systematic review and meta-analysis. Diabetes Care. 2016;39(5):833\u201346.","journal-title":"Diabetes Care"},{"issue":"2","key":"2354_CR10","doi-asserted-by":"publisher","first-page":"639","DOI":"10.2337\/db12-0495","volume":"62","author":"A Floegel","year":"2013","unstructured":"Floegel A, Stefan N, Yu Z, M\u00fchlenbruch K, Drogan D, Joost HG, et al. Identification of serum metabolites associated with risk of type 2 diabetes using a targeted metabolomic approach. Diabetes. 2013;62(2):639\u201348.","journal-title":"Diabetes"},{"issue":"5","key":"2354_CR11","doi-asserted-by":"publisher","first-page":"1507","DOI":"10.1093\/ije\/dyw221","volume":"45","author":"G Qiu","year":"2016","unstructured":"Qiu G, Zheng Y, Wang H, Sun J, Ma H, Xiao Y, et al. Plasma metabolomics identified novel metabolites associated with risk of type 2 diabetes in two prospective cohorts of Chinese adults. Int J Epidemiol. 2016;45(5):1507\u201316.","journal-title":"Int J Epidemiol"},{"issue":"4","key":"2354_CR12","doi-asserted-by":"publisher","first-page":"448","DOI":"10.1038\/nm.2307","volume":"17","author":"TJ Wang","year":"2011","unstructured":"Wang TJ, Larson MG, Vasan RS, Cheng S, Rhee EP, McCabe E, et al. Metabolite profiles and the risk of developing diabetes. Nat Med. 2011;17(4):448\u201353.","journal-title":"Nat Med"},{"key":"2354_CR13","doi-asserted-by":"publisher","first-page":"615","DOI":"10.1038\/msb.2012.43","volume":"8","author":"R Wang-Sattler","year":"2012","unstructured":"Wang-Sattler R, Yu Z, Herder C, Messias AC, Floegel A, He Y, et al. Novel biomarkers for pre-diabetes identified by metabolomics. Mol Syst Biol. 2012;8:615.","journal-title":"Mol Syst Biol"},{"issue":"5","key":"2354_CR14","doi-asserted-by":"publisher","first-page":"1730","DOI":"10.2337\/db12-0707","volume":"62","author":"E Ferrannini","year":"2013","unstructured":"Ferrannini E, Natali A, Camastra S, Nannipieri M, Mari A, Adam KP, et al. Early metabolic markers of the development of dysglycemia and type 2 diabetes and their physiological significance. Diabetes. 2013;62(5):1730\u20137.","journal-title":"Diabetes"},{"issue":"5","key":"2354_CR15","doi-asserted-by":"publisher","first-page":"968","DOI":"10.1007\/s00125-015-3517-8","volume":"58","author":"T Tillin","year":"2015","unstructured":"Tillin T, Hughes AD, Wang Q, W\u00fcrtz P, Ala-Korpela M, Sattar N, et al. Diabetes risk and amino acid profiles: cross-sectional and prospective analyses of ethnicity, amino acids and diabetes in a south Asian and European cohort from the SABRE (Southall and Brent REvisited) study. Diabetologia. 2015;58(5):968\u201379.","journal-title":"Diabetologia"},{"issue":"2","key":"2354_CR16","doi-asserted-by":"publisher","first-page":"220","DOI":"10.2337\/dc14-2033","volume":"38","author":"J Zhao","year":"2015","unstructured":"Zhao J, Zhu Y, Hyun N, Zeng D, Uppal K, Tran VT, et al. Novel metabolic markers for the risk of diabetes development in American Indians. Diabetes Care. 2015;38(2):220\u20137.","journal-title":"Diabetes Care"},{"issue":"9","key":"2354_CR17","doi-asserted-by":"publisher","first-page":"1740","DOI":"10.1007\/s00125-017-4325-0","volume":"60","author":"G Peddinti","year":"2017","unstructured":"Peddinti G, Cobb J, Yengo L, Froguel P, Kravi\u0107 J, Balkau B, et al. Early metabolic markers identify potential targets for the prevention of type 2 diabetes. Diabetologia. 2017;60(9):1740\u201350.","journal-title":"Diabetologia"},{"issue":"3","key":"2354_CR18","doi-asserted-by":"publisher","first-page":"e1001779","DOI":"10.1371\/journal.pmed.1001779","volume":"12","author":"C Sudlow","year":"2015","unstructured":"Sudlow C, Gallacher J, Allen N, Beral V, Burton P, Danesh J, et al. UK Biobank: an open access resource for identifying the causes of a wide range of complex diseases of middle and old age. PLoS Med. 2015;12(3):e1001779.","journal-title":"PLoS Med"},{"key":"2354_CR19","doi-asserted-by":"publisher","first-page":"222","DOI":"10.12688\/wellcomeopenres.16171.2","volume":"5","author":"N Allen","year":"2021","unstructured":"Allen N, Arnold M, Parish S, Hill M, Sheard S, Callen H, et al. Approaches to minimising the epidemiological impact of sources of systematic and random variation that may affect biochemistry assay data in UK Biobank. Wellcome Open Res. 2021;5:222.","journal-title":"Wellcome Open Res"},{"issue":"1","key":"2354_CR20","doi-asserted-by":"publisher","first-page":"2624","DOI":"10.1038\/s41467-020-15948-9","volume":"11","author":"TJ Littlejohns","year":"2020","unstructured":"Littlejohns TJ, Holliday J, Gibson LM, Garratt S, Oesingmann N, Alfaro-Almagro F, et al. The UK Biobank imaging enhancement of 100,000 participants: rationale, data collection, management and future directions. Nat Commun. 2020;11(1):2624.","journal-title":"Nat Commun"},{"key":"2354_CR21","volume-title":"Repeat assessment data, version 1.0: UK biobank","author":"UK Biobank","year":"2013","unstructured":"UK Biobank. Repeat assessment data, version 1.0: UK Biobank; 2013."},{"issue":"9","key":"2354_CR22","doi-asserted-by":"publisher","first-page":"1084","DOI":"10.1093\/aje\/kwx016","volume":"186","author":"P W\u00fcrtz","year":"2017","unstructured":"W\u00fcrtz P, Kangas AJ, Soininen P, Lawlor DA, Davey Smith G, Ala-Korpela M. Quantitative serum nuclear magnetic resonance metabolomics in large-scale epidemiology: a primer on -omic technologies. Am J Epidemiol. 2017;186(9):1084\u201396.","journal-title":"Am J Epidemiol"},{"issue":"1","key":"2354_CR23","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1161\/CIRCGENETICS.114.000216","volume":"8","author":"P Soininen","year":"2015","unstructured":"Soininen P, Kangas AJ, W\u00fcrtz P, Suna T, Ala-Korpela M. Quantitative serum nuclear magnetic resonance metabolomics in cardiovascular epidemiology and genetics. Circ Cardiovasc Genet. 2015;8(1):192\u2013206.","journal-title":"Circ Cardiovasc Genet"},{"key":"2354_CR24","doi-asserted-by":"publisher","first-page":"e63033","DOI":"10.7554\/eLife.63033","volume":"10","author":"H Julkunen","year":"2021","unstructured":"Julkunen H, Cicho\u0144ska A, Slagboom PE, W\u00fcrtz P, Nightingale Health UKBI. Metabolic biomarker profiling for identification of susceptibility to severe pneumonia and COVID-19 in the general population. Elife. 2021;10:e63033.","journal-title":"Elife"},{"issue":"1","key":"2354_CR25","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1111\/j.2517-6161.1995.tb02031.x","volume":"57","author":"Y Benjamini","year":"1995","unstructured":"Benjamini Y, Hochberg Y. Controlling the false discovery rate: a practical and powerful approach to multiple testing. J R Stat Soc Ser B Methodol. 1995;57(1):289\u2013300.","journal-title":"J R Stat Soc Ser B Methodol"},{"issue":"4","key":"2354_CR26","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1002\/(SICI)1097-0258(19960229)15:4<361::AID-SIM168>3.0.CO;2-4","volume":"15","author":"FE Harrell Jr","year":"1996","unstructured":"Harrell FE Jr, Lee KL, Mark DB. Multivariable prognostic models: issues in developing models, evaluating assumptions and adequacy, and measuring and reducing errors. Stat Med. 1996;15(4):361\u201387.","journal-title":"Stat Med"},{"issue":"2","key":"2354_CR27","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1002\/sim.2929","volume":"27","author":"MJ Pencina","year":"2008","unstructured":"Pencina MJ, D\u2019Agostino RB Sr, D\u2019Agostino RB Jr, Vasan RS. Evaluating the added predictive ability of a new marker: from area under the ROC curve to reclassification and beyond. Stat Med. 2008;27(2):157\u201372.","journal-title":"Stat Med"},{"issue":"1","key":"2354_CR28","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1002\/sim.4085","volume":"30","author":"MJ Pencina","year":"2011","unstructured":"Pencina MJ, D\u2019Agostino RB Sr, Steyerberg EW. Extensions of net reclassification improvement calculations to measure usefulness of new biomarkers. Stat Med. 2011;30(1):11\u201321.","journal-title":"Stat Med"},{"issue":"12","key":"2354_CR29","doi-asserted-by":"publisher","first-page":"2298","DOI":"10.1007\/s00125-019-05001-w","volume":"62","author":"AV Ahola-Olli","year":"2019","unstructured":"Ahola-Olli AV, Mustelin L, Kalimeri M, Kettunen J, Jokelainen J, Auvinen J, et al. Circulating metabolites and the risk of type 2 diabetes: a prospective study of 11,896 young adults from four Finnish cohorts. Diabetologia. 2019;62(12):2298\u2013309.","journal-title":"Diabetologia"},{"issue":"4","key":"2354_CR30","doi-asserted-by":"publisher","first-page":"628","DOI":"10.2337\/dc14-0645","volume":"38","author":"RH Mackey","year":"2015","unstructured":"Mackey RH, Mora S, Bertoni AG, Wassel CL, Carnethon MR, Sibley CT, et al. Lipoprotein particles and incident type 2 diabetes in the multi-ethnic study of atherosclerosis. Diabetes Care. 2015;38(4):628\u201336.","journal-title":"Diabetes Care"},{"issue":"2","key":"2354_CR31","doi-asserted-by":"publisher","first-page":"453","DOI":"10.2337\/diabetes.52.2.453","volume":"52","author":"WT Garvey","year":"2003","unstructured":"Garvey WT, Kwon S, Zheng D, Shaughnessy S, Wallace P, Hutto A, et al. Effects of insulin resistance and type 2 diabetes on lipoprotein subclass particle size and concentration determined by nuclear magnetic resonance. Diabetes. 2003;52(2):453\u201362.","journal-title":"Diabetes"},{"issue":"5","key":"2354_CR32","doi-asserted-by":"publisher","first-page":"873","DOI":"10.1007\/s00125-017-4222-6","volume":"60","author":"Y Mahendran","year":"2017","unstructured":"Mahendran Y, Jonsson A, Have CT, Allin KH, Witte DR, J\u00f8rgensen ME, et al. Genetic evidence of a causal effect of insulin resistance on branched-chain amino acid levels. Diabetologia. 2017;60(5):873\u20138.","journal-title":"Diabetologia"},{"issue":"11","key":"2354_CR33","doi-asserted-by":"publisher","first-page":"e1002179","DOI":"10.1371\/journal.pmed.1002179","volume":"13","author":"LA Lotta","year":"2016","unstructured":"Lotta LA, Scott RA, Sharp SJ, Burgess S, Luan J, Tillin T, et al. Genetic predisposition to an impaired metabolism of the branched-chain amino acids and risk of type 2 diabetes: a Mendelian randomisation analysis. PLoS Med. 2016;13(11):e1002179.","journal-title":"PLoS Med"},{"key":"2354_CR34","doi-asserted-by":"publisher","first-page":"1133","DOI":"10.2337\/dc20-2426","volume":"44","author":"F Qian","year":"2021","unstructured":"Qian F, Ardisson Korat AV, Imamura F, Marklund M, Tintle N, Virtanen JK, et al. N-3 fatty acid biomarkers and incident type 2 diabetes: an individual participant-level pooling project of 20 prospective cohort studies. Diabetes Care. 2021;44:1133\u201342.","journal-title":"Diabetes Care"},{"issue":"8","key":"2354_CR35","doi-asserted-by":"publisher","first-page":"444","DOI":"10.1038\/s41574-018-0045-x","volume":"14","author":"E Pearson","year":"2018","unstructured":"Pearson E, Adamski J. The search for predictive metabolic biomarkers for incident T2DM. Nat Rev Endocrinol. 2018;14(8):444\u20136.","journal-title":"Nat Rev Endocrinol"},{"issue":"10","key":"2354_CR36","doi-asserted-by":"publisher","first-page":"2114","DOI":"10.1007\/s00125-016-4041-1","volume":"59","author":"T Fall","year":"2016","unstructured":"Fall T, Salihovic S, Brandmaier S, Nowak C, Ganna A, Gustafsson S, et al. Non-targeted metabolomics combined with genetic analyses identifies bile acid synthesis and phospholipid metabolism as being associated with incident type 2 diabetes. Diabetologia. 2016;59(10):2114\u201324.","journal-title":"Diabetologia"},{"issue":"1","key":"2354_CR37","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1007\/s00125-013-3061-3","volume":"57","author":"C Herder","year":"2014","unstructured":"Herder C, Kowall B, Tabak AG, Rathmann W. The potential of novel biomarkers to improve risk prediction of type 2 diabetes. Diabetologia. 2014;57(1):16\u201329.","journal-title":"Diabetologia"},{"key":"2354_CR38","doi-asserted-by":"publisher","unstructured":"Tikkanen E, J\u00e4gerroos V, Rodosthenous R, Holmes MV, Sattar N, Ala-Korpela M, Jousilahti P, Lundqvist A, Perola M, Salomaa V et al. Metabolic Biomarkers for Peripheral Artery Disease Compared with Coronary Artery Disease: Lipoprotein and metabolite profiling of 31,657 individuals from five prospective cohorts. medRxiv. 2020.07.24.20158675. https:\/\/doi.org\/10.1101\/2020.07.24.20158675.","DOI":"10.1101\/2020.07.24.20158675"},{"issue":"6","key":"2354_CR39","doi-asserted-by":"publisher","first-page":"e0218549","DOI":"10.1371\/journal.pone.0218549","volume":"14","author":"R Li-Gao","year":"2019","unstructured":"Li-Gao R, Hughes DA, le Cessie S, de Mutsert R, den Heijer M, Rosendaal FR. Willems van Dijk K, Timpson NJ, Mook-Kanamori DO: assessment of reproducibility and biological variability of fasting and postprandial plasma metabolite concentrations using 1H NMR spectroscopy. PLoS One. 2019;14(6):e0218549.","journal-title":"PLoS One"},{"issue":"9","key":"2354_CR40","doi-asserted-by":"publisher","first-page":"1026","DOI":"10.1093\/aje\/kwx246","volume":"186","author":"A Fry","year":"2017","unstructured":"Fry A, Littlejohns TJ, Sudlow C, Doherty N, Adamska L, Sprosen T, et al. Comparison of sociodemographic and health-related characteristics of UK Biobank participants with those of the general population. Am J Epidemiol. 2017;186(9):1026\u201334.","journal-title":"Am J Epidemiol"},{"key":"2354_CR41","doi-asserted-by":"publisher","first-page":"m131","DOI":"10.1136\/bmj.m131","volume":"368","author":"GD Batty","year":"2020","unstructured":"Batty GD, Gale CR, Kivim\u00e4ki M, Deary IJ, Bell S. Comparison of risk factor associations in UK Biobank against representative, general population based studies with conventional response rates: prospective cohort study and individual participant meta-analysis. BMJ. 2020;368:m131.","journal-title":"BMJ"}],"container-title":["BMC Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12916-022-02354-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12916-022-02354-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12916-022-02354-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,9,23]],"date-time":"2024-09-23T12:12:41Z","timestamp":1727093561000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcmedicine.biomedcentral.com\/articles\/10.1186\/s12916-022-02354-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,5,3]]},"references-count":41,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,12]]}},"alternative-id":["2354"],"URL":"https:\/\/doi.org\/10.1186\/s12916-022-02354-9","relation":{"has-preprint":[{"id-type":"doi","id":"10.1101\/2021.10.11.21264833","asserted-by":"object"}]},"ISSN":["1741-7015"],"issn-type":[{"value":"1741-7015","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,5,3]]},"assertion":[{"value":"1 December 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 March 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 May 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Ethics approval for the UK Biobank was obtained from the North West Multi-centre Research Ethics Committee (Ref: 11\/NW\/0382). All participants provided informed written consent.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"159"}}